Management of Atrial Fibrillation When Patient Declines Anticoagulation
When a patient with atrial fibrillation refuses anticoagulation, you must first calculate their CHA₂DS₂-VA score (the updated version without sex as a criterion) to quantify their stroke risk, then implement rate control therapy and consider left atrial appendage occlusion as an alternative stroke prevention strategy if they have elevated thromboembolic risk. 1, 2
Risk Stratification Using CHA₂DS₂-VA Score
The 2024 ESC guidelines have simplified stroke risk assessment by removing sex from the scoring system, creating the CHA₂DS₂-VA score 2, 3. Calculate points as follows:
- Chronic heart failure (any symptoms/signs or LVEF ≤40%): 1 point
- Hypertension (BP >140/90 or on treatment): 1 point
- Age ≥75 years: 2 points
- Diabetes mellitus: 1 point
- Prior Stroke/TIA/arterial thromboembolism: 2 points
- Vascular disease (CAD, prior MI, revascularization): 1 point
- Age 65-74 years: 1 point
A score ≥2 indicates high risk where anticoagulation is strongly recommended; a score of 1 indicates intermediate risk where anticoagulation should be considered. 2
Critical Counseling Point
Document a thorough informed consent discussion explaining that anticoagulation reduces stroke risk by approximately 64% and that declining therapy substantially increases their risk of disabling or fatal stroke. 4 Many AF-related strokes are fatal or severely debilitating, and most could be prevented with proper anticoagulation 4.
Alternative Stroke Prevention Strategy
Left Atrial Appendage Occlusion
For patients with contraindications to long-term anticoagulation or persistent refusal despite counseling, left atrial appendage occlusion (LAAO) may be considered as an alternative stroke prevention strategy. 5, 6 This interventional approach mechanically excludes the left atrial appendage, the source of most AF-related thrombi, without requiring chronic anticoagulation.
Common pitfall: LAAO still requires short-term anticoagulation or dual antiplatelet therapy post-procedure, so ensure the patient understands this is not a complete avoidance of all antithrombotic therapy.
What NOT to Do
Antiplatelet therapy (aspirin or other antiplatelet agents) is NOT recommended as an alternative to anticoagulation for stroke prevention in AF. 2 This is a Class III recommendation (harm) in current guidelines—aspirin provides minimal stroke protection in AF while still carrying bleeding risk.
Rate Control Management
Since rhythm control versus rate control does not affect mortality 7, implement rate control therapy:
First-line rate control options:
- Beta-blockers (preferred in most patients)
- Non-dihydropyridine calcium channel blockers (diltiazem or verapamil)
- Digoxin (particularly useful in heart failure patients or as add-on therapy)
Target resting heart rate <110 bpm for lenient rate control, which is generally adequate for most patients 1, 3.
Rhythm Control Considerations
If the patient remains highly symptomatic despite rate control:
- Amiodarone is preferred for patients with heart failure or reduced LVEF 7, 3
- Flecainide can be used in patients with structurally normal hearts 3
- Dronedarone is an option with relatively fewer side effects but contraindicated in decompensated heart failure 7
- Pulmonary vein isolation is now recommended as first-line treatment for paroxysmal AF and should be strongly considered for symptomatic patients 2, 3
Mandatory Ongoing Management
Periodic Reassessment
Individualized reassessment of thromboembolic risk is required at regular intervals because stroke risk is dynamic and changes over time with aging and development of new comorbidities 2, 6. Many patients initially at low risk will progress to higher risk categories requiring anticoagulation.
Risk Factor Modification
Aggressively manage modifiable cardiovascular risk factors 2, 3:
- Optimize blood pressure control (target 120-129/70-79 mmHg)
- Treat heart failure across all LVEF ranges with SGLT2 inhibitors 2, 3
- Manage diabetes, sleep apnea, obesity, and other comorbidities
- Address lifestyle factors (alcohol reduction, weight loss)
Arrhythmia Monitoring
Consider digital health technologies and wearable devices for ongoing AF burden assessment, as increased AF burden may warrant reconsideration of anticoagulation 6.
Documentation Requirements
Document in the medical record:
- Calculated CHA₂DS₂-VA score with specific stroke risk percentage
- Detailed discussion of anticoagulation benefits and risks of refusal
- Patient's specific reasons for declining anticoagulation
- Alternative strategies offered (LAAO discussion)
- Plan for periodic reassessment of both stroke risk and patient preferences
The patient's refusal should be revisited at every follow-up visit, as preferences may change and stroke risk inevitably increases with time.